乳腺癌骨转移的内科治疗

doi:10.3760/cma.j.issn.1673-422X.2015.12.010

摘要/Abstract

摘要： 晚期乳腺癌中约70%的患者最终会发生骨转移，骨转移可导致骨相关事件等一系列并发症，严重影响患者的生命质量。因此，选择合理有效的治疗手段非常重要。双膦酸盐是目前乳腺癌骨转移的标准治疗方法，而抗体类新药地诺单抗可能成为双膦酸盐的合理替代物，化疗、内分泌及靶向治疗亦是晚期乳腺癌的基础治疗，只有将各种治疗手段联合应用才能获得最佳疗效。

关键词: 乳腺肿瘤, 肿瘤转移, 治疗, 骨相关事件

Abstract: Approximately 70% advanced breast cancer will develop bone metastases. Bone metastases can cause a series of complications such as skeletalrelated events, seriously affecting the quality of life of the patients. Therefore, it is very important to choose the reasonable and effective treatments. Bisphosphonates are the standard treatments of bone metastatic breast cancer, denosumab may also be a reasonable alternative to bisphosphonates in the near future, while chemotherapy, endocrinotherapy and targeted therapy are the basic treatments of advanced breast cancer, combined use of various treatments will get the best efficacy.

Key words: Breast neoplasms, Neoplasm metastasis, Therapy, Skeletal-related event

谢晓娟,佟仲生. 乳腺癌骨转移的内科治疗[J]. 国际肿瘤学杂志, 2015, 42(12): 920-923.

Xie Xiaojuan, Tong Zhongsheng. |Medical therapy of bone metastases of breast cancer[J]. Journal of International Oncology, 2015, 42(12): 920-923.

参考文献

［1］张思嘉，马迪，何仲．肥胖与乳腺癌关系的研究进展［J］．肿瘤防治研究， 2012， 39（10）： 1265-1268．［2］ Rucci N, Sanità P, Delle Monache S, et al. Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets［J］. World J Clin Oncol, 2014, 5(3): 335-347. ［3］ Wang X, Yang KH, Wanyan P, et al. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A metaanalysis of randomized controlled trials［J］. Oncol Lett, 2014, 7(6): 1997-2002. ［4］ Harries M, Taylor A, Holmberg L, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients［J］. Cancer Epidemiol, 2014, 38(4): 427-434. ［5］ Diamond JR, Finlayson CA, Borges VF. Hepatic complications of breast cancer［J］. Lancet Oncol, 2009, 10(6): 615-621. ［6］孙姗姗，张月蒙，高英杰，等．骨改良药治疗骨转移的研究进展［J］．国际肿瘤学杂志， 2014， 41（3）： 226-228．［7］ Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review)［J］. Oncol Lett, 2013, 6(2): 306-310. ［8］董梅，陈学鹏，冯奉仪．双膦酸盐治疗恶性肿瘤骨转移的研究进展［J］．中华肿瘤杂志， 2007， 32（11）： 801-803．［9］ Mathew A, Brufsky A. Bisphosphonates in breast cancer［J］. Int J Cancer, 2015, 137(4): 753-764. ［10］ Keizman D, IshShalom M, Pili R, et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma［J］. Eur J Cancer, 2012, 48(7): 1031-1037. ［11］胡洁芬，陈懿，吴文．双膦酸盐的发展及临床应用［J］．中华关节外科杂志:电子版， 2013， 7（2）： 265-268．［12］ Paterson AH, Powles TJ, Kanis JA, et al. Doubleblind controlled trial of oral clodronate in patients with bone metastases from breast cancer［J］. J Clin Oncol, 1993, 11(1): 59-65. ［13］ Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term followup of two randomized, placebocontrolled trials［J］. Cancer, 2000, 88(5): 1082-1090. ［14］ Hortobagyi GN, Theriault RL, Lipton A, et al. Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group［J］. J Clin Oncol, 1998, 16(6): 2038-2044. ［15］ Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebocontrolled trial. Protocol 18 Aredia Breast Cancer Study Group［J］. J Clin Oncol, 1999, 17(3): 846-854. ［16］ Rosen LS, Gordon D, Kaminski M, et al. Longterm efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial［J］. Cancer, 2003, 98(8): 1735-1744. ［17］ Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion［J］. Cancer, 2004, 100(1): 36-43. ［18］ Amadori D, Aglietta M, Alessi B, et al. Efficacy and safety of 12weekly versus 4weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, openlabel, randomised, noninferiority trial［J］. Lancet Oncol, 2013, 14(7): 663-670. ［19］ Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases［J］. Ann Oncol, 2003, 14(9): 1399-1405. ［20］ Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebocontrolled phase Ⅲ studies［J］. Br J Cancer, 2004, 90(6): 1133-1137. ［21］ BarrettLee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, noninferiority phase 3 trial［J］. Lancet Oncol, 2014, 15(1): 114-122. ［22］中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2013版)［J］．中国癌症杂志， 2013（8）： 637-693．［23］ Ding X, Fan Y, Ma F, et al. Prolonged administration of bisphosphonates is welltolerated and effective for skeletalrelated events in Chinese breast cancer patients with bone metastasis［J］. Breast, 2012, 21(4): 544-549. ［24］ Kumar V, Shahi AK. Nitrogen containing bisphosphonates associated osteonecrosis of the Jaws: A review for past 10 year literature［J］. Dent Res J (Isfahan), 2014, 11(2): 147-153. ［25］ Boyce BF, Xing LP. Biology of RANK, RANKL, and osteoprotegerin［J］. Arthritis Res Ther, 2007, 9(Suppl 1): S1. ［26］许宋锋， Adams B, 于秀淳，等．骨巨细胞瘤治疗新突破——狄诺塞麦［J］．国际骨科学杂志， 2013， 34（6）： 387-392．［27］乔光磊，郑水儿，祁伟祥，等．狄诺塞麦与唑来膦酸治疗恶性实体瘤骨转移和多发性骨髓瘤骨相关事件的疗效和安全性的比较: 一项Meta分析［J］．肿瘤， 2013， 33（1）： 48-57．［28］ Barton MK. Denosumab an option for patients with bone metastasis from breast cancer［J］. CA Cancer J Clin, 2011, 61(3): 135-136. ［29］ Smith MR, Saad F, Coleman R, et al. Denosumab and bonemetastasisfree survival in men with castrationresistant prostate cancer: results of a phase 3, randomised, placebocontrolled trial［J］. Lancet, 2012, 379(9810): 39-46. ［30］ Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011［J］. Ann Oncol, 2011, 22(8): 1736-1747. ［31］黄曼，郭保凤，吴金娜，等．靶向治疗乳腺癌骨转移的研究进展［J］．现代生物医学进展， 2013， 13（1）： 184-186, 111．

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[14]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[15]	岳红云, 张百红. 肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.